| Balance Sheets | 2025-08-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 15,111 | |||
| Prepaid expenses and other receivables | 3,326 | |||
| Total current assets | 18,437 | |||
| Equipment, net | 0 | |||
| Total assets | 18,437 | |||
| Accounts payable and accrued liabilities | 49,252 | |||
| Convertible loan | 1,197,257 | |||
| Due to a related party | 1,268,221 | |||
| Total current liabilities | 2,514,730 | |||
| Common stock, 0.0001par value,1,800,000,000and900,000,000shares authorized on august 31, 2025 and august 31, 2024 respectively. 553,962,206and31,111,352shares issued and outstanding on august 31, 2025 and august 31, 2024 respectively | 55,396 | |||
| Additional paid-in capital | 22,716,687 | |||
| Accumulated deficit | -25,268,376 | |||
| Total stockholders' equity (deficit) | -2,496,293 | |||
| Total liabilities and stockholders' equity | 18,437 | |||
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)